Primary Sjögren's Syndrome Clinical Trial
Official title:
Reliability, Validity, and Cross-Cultural Adaptation of the Turkish Version of the Primary Sjögren Syndrome Quality of Life (PSS-QoL) Questionnaire
The purpose of this study was to investigate adaptation, validity, and reliability of the Turkish version of the Primary Sjögren's Syndrome Quality of Life (PSS-QoL) Questionnaire
Primary Sjögren's Syndrome (PSS) is a chronic systemic disease characterized by lymphocytic infiltration of exocrine glands. Dryness, chronic pain, physical fatigue, glandular and extraglandular symptoms seen in PSS cause deterioration of the health-related quality of life. The Primary Sjögren's Syndrome Quality of Life (PSS-QoL) Questionnaire has recently developed as a patient-reported condition-specific outcome measurement tool to assess the quality of life associated with PSS. The PSS-QoL questionnaire consists of 25 questions with a physical and psychosocial dimension.The physical dimension consists of a numeric rating scale (NRS, ranging from 0 to 10) for pain and physical symptoms. The question related to vaginal dryness is intended to be answered by women only. Each "yes" answer about physical symptoms-related questions adds 1 point to the score. The psychosocial dimension can be scored on a 5-point Likert scale and contains 14 question with the following possible answers: never (0), rarely (1), sometimes (2), often (3), and always (4). The PSS-QoL score ranges from 0-96 (for women) and 0-92 (excluding the question of vaginal dryness for men). After questioning the sociodemographic characteristics of the individuals, PSS-QoL, EuroQuol-5D, the EULAR Sjögren's Syndrome Disease Activity Index and EULAR Sjögren's Syndrome Patient Reported Index will be used. Test-retest will be re-applied to those of the same individuals who can be reached after 1 week. The results will be analyzed using the SPSS version 22.0 computer package program. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03040583 -
The ASSESS National Multi-center Prospective Cohort
|
||
| Completed |
NCT01989819 -
Primary Sjögren Syndrome
|
||
| Completed |
NCT02291029 -
Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
| Terminated |
NCT02610543 -
UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
| Not yet recruiting |
NCT04975087 -
The Profile of Fatigue and Discomfort - Sicca Symptoms Inventory
|
||
| Recruiting |
NCT06203457 -
Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
| Completed |
NCT04078386 -
A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome
|
Phase 2 | |
| Recruiting |
NCT05087589 -
Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome
|
Phase 2 | |
| Recruiting |
NCT04212572 -
Ultrasound Abnormalities of the Salivary Glands in Primary Sjögren's Syndrome According to the Duration of the Disease
|
||
| Completed |
NCT02149420 -
PD of VAY736 in Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
| Recruiting |
NCT03003572 -
Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity
|
||
| Completed |
NCT00632866 -
Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome
|
Phase 3 | |
| Completed |
NCT02334306 -
A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome
|
Phase 2 | |
| Completed |
NCT02775916 -
Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
| Completed |
NCT02464319 -
A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome
|
Phase 2 | |
| Terminated |
NCT01552681 -
Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome
|
Phase 2 | |
| Completed |
NCT04186871 -
Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
|
Phase 2 | |
| Completed |
NCT00426543 -
Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
| Recruiting |
NCT04981145 -
The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome
|
Phase 4 | |
| Completed |
NCT03627065 -
A Study of INCB050465 in Primary Sjögren's Syndrome
|
Phase 2 |